Bitcoin set for a rebound that could stretch toward $100000, BTIG says
Investing.com - Bernstein SocGen Group has raised its price target on Sarepta Therapeutics (NASDAQ:SRPT) to $20.00 from $18.00 while maintaining a Market Perform rating. Sarepta shares currently trade at $18.91, having gained 8.43% over the past week despite falling over 83% in the past year.
The firm cited higher Elevidys estimates following solid Q3 results and a recent label update for the Duchenne muscular dystrophy (DMD) treatment as key factors behind the adjustment. The company reported $2.41 billion in revenue over the last twelve months, with 47.15% revenue growth.
Bernstein noted that the risk of market withdrawal for Sarepta’s skipper product following the ESSENCE trial miss is "likely overblown (though certainly non-zero)."
The firm expressed caution regarding upcoming catalysts, particularly data for DM1 and FSHD expected in early 2026. Bernstein observed that the DM1 cohort 5 dosage has been increased to 12 mpk from the previously listed 6 mpk in the July 2025 restructuring presentation.
For the FSHD data, Bernstein expects results to "look competitive given dosing is up to 12 mpk," potentially showing over 40% reduction in DUX4-regulated gene expression, with no immediate need to demonstrate functional benefits.
In other recent news, Sarepta Therapeutics has made significant progress in its clinical studies and received notable updates regarding its treatments. The company announced advancements in its Phase 1/2 clinical trial for SRP-1003, targeting type 1 myotonic dystrophy, with completed dosing cohorts and ongoing higher doses. Meanwhile, Sarepta’s gene therapy for Duchenne muscular dystrophy, Elevidys, received updated labeling from the FDA, including a boxed warning for acute liver injury risks, although the therapy remains approved for ambulatory patients aged four and older.
Mizuho has shown confidence in Sarepta by upgrading its stock rating from Neutral to Outperform, raising the price target to $26.00. This upgrade reflects strong demand for Elevidys and favorable insurance coverage, despite safety concerns and a commercial pause. Additionally, Mizuho reaffirmed an Outperform rating, emphasizing Sarepta’s potential despite recent stock volatility. These developments highlight the ongoing interest and potential challenges in Sarepta’s therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.